VRAX (Virax Biolabs Group) Treasury Stock : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Virax Biolabs Group's treasury stock for the quarter that ended in Sep. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Virax Biolabs Group Treasury Stock Historical Data

The historical data trend for Virax Biolabs Group's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Treasury Stock Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Treasury Stock

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Treasury Stock	Get a 7-Day Free Trial					-	-	-	-	-

Virax Biolabs Group Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.